Aug. 16, 2004 - Natural Products Industry INSIDER

Aug. 16, 2004 - Natural Products Industry INSIDER
"Emotional Wellness" References

1. Kessler RC et al. "The epidemiology of major depressive disorder:results from the National Comorbidity Survey Replication (NCS-R)." JAMA.289, 23:3095-105, 2003. www.jama.com.

2. Jorm AF et al. "Effectiveness of complementary and self-helptreatments for depression." Med J Aust. 176 Suppl:S84-96, 2002. www.mja.com.au.

3. Morris MS et al. "Depression and folate status in the U.S.population." Psychother Psychosom. 72, 2:80-7, 2003. http://content.karger.com/ProdukteDB/produkte.asp?Aktion=JournalHome&ProduktNr=223864

4. Tolmunen T et al. "Dietary folate and depressive symptoms areassociated in middle-aged Finnish men." J Nutr. 133, 10:3233-6,2003. www.nutrition.org

5. Taylor MJ et al. "Folate for depressive disorders." CochraneDatabase Syst Rev. 2:CD003390, 2003. www.cochrane.org

6. Alpert M, Silva RR, Pouget ER. "Prediction of treatment response ingeriatric depression from baseline folate level: interaction with an SSRI or atricyclic antidepressant." J Clin Psychopharmacol. 23, 3:309-13,2003. www.psychopharmacology.com/pt/re/jclnpsychopharm/

7. Coppen A, Bailey J. "Enhancement of the antidepressant action offluoxetine by folic acid: a randomized, placebo-controlled trial." JAffect Disord. 60, 2:121-30, 2000. www.elsevier.nl/locate/jad

8. Bjelland I et al. "Folate, vitamin B12, homocysteine and the MTHFR677C-T polymorphism in anxiety and depression: the Hordaland HomocysteineStudy." Arch Gen Psychiatry. 60, 6:618-26, 2003. http://archpsyc.ama-assn.org

9. Tiemeier H et al. "Vitamin B12, folate and homocysteine indepression: the Rotterdam Study." Am J Psychiatry. 159, 12:2099-101,2002. http://ajp.psychiatryonline.org

10. Hintikka J et al. "High vitamin B12 level and good treatment outcomemay be associated in major depressive disorder." BMC Psychiatry. 3,1:17, 2003. www.biomedcentral.com/bmcpsychiatry

11. Taylor M et al. "Inositol for depressive disorders." CochraneDatabase Syst Rev. 2:CD004049, 2004. www.cochrane.org

12. Einat H et al. "Chronic inositol treatment reduces depression-likeimmobility of Flinders Sensitive Line rats in the forced swim test." DepressAnxiety. 15, 3:148-51, 2002. www3.interscience.wiley.com/cgi-bin/jhome/38924

13. Palatnik A et al. "Double blind, controlled, crossover trial ofinositol versus fluvoxamine for the treatment of panic disorder." J ClinPsychopharmacol. 21, 3:335-9, 2001. www.psychopharmacology.com/pt/re/jclnpsychopharm

14. McLeod MN, Golden RN. "Chromium treatment of depression." IntJ Neuropsychopharmacol. 3:311-14, 2000. http://uk.cambridge.org/journals/pnp

15. Davidson JR et al. "Effectiveness of chromium in atypicaldepression: a placebo-controlled trial." Biol Psychiatry. 53:261-64,2003. www.sciencedirect.com/science/journal/00063223

16. Docherty JP et al. "Chromium picolinate: atypical depression,carbohydrate craving and clinical response." Presented at the 44th AnnualMeeting of the New Clinical Drug Evaluation Unit, June 1 to 4, 2004, Phoenix.

17. Papakostas GI, Alpert JE, Fava M. "S-adenosyl-methionine indepression: a comprehensive review of the literature." Curr PsychiatryRep. 5, 6:460-6, 2003. www.current-reports.com/home_journal.cfm?JournalID=PR

18. Mischoulon D, Fava M. "Role of S-adenosyl-L-methionine in thetreatment of depression: a review of the evidence." Am J Clin Nutr.76, 5:1158S-61S, 2002. www.ajcn.org

19. Genedani S et al. "Influence of SAMe on the modifications of brainpolyamine levels in an animal model of depression." Neuroreport. 12,18:3939-42, 2001. www.neuroreport.com

20. Silveri MM et al. "S-adenosyl-L-methionine: effects on brainbioenergetic status and transverse relaxation time in healthy subjects." BiolPsychiatry. 54, 8:833-9, 2003. www.sciencedirect.com/science/journal/00063223

21. Pancheri P, Scapicchio P, Chiaie RD. "A double blind, randomizedparallel-group, efficacy and safety study of intramuscularS-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine inpatients with major depressive disorder." Int J Neuropsychopharmacol.5, 4:287-94, 2002. http://uk.cambridge.org/journals/pnp

22. Chiaie RD, Pancheri P, Scapicchio P. "Efficacy and tolerability oforal and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) inthe treatment of major depression: comparison with imipramine in 2 multicenterstudies." Am J Clin Nutr. 76, 5:1172S-6S, 2002. www.ajcn.org

23. Das YT et al. "Safety of 5-hydroxy-L-tryptophan." ToxicolLett. 150, 1:111-22, 2004. www.sciencedirect.com/science/journal/03784274

24. Shaw K, Turner J, Del Mar C. "Tryptophan and 5-hydroxytryptophan fordepression." Cochrane Database Syst Rev. 1:CD003198, 2002. www.cochrane.org

25. Schruers K et al. "Acute L-5-hydroxytryptophan administrationinhibits carbon dioxide-induced panic in panic disorder patients." PsychiatryRes. 113, 3:237-43, 2002. www.sciencedirect.com/science/journal/09254927

26. Pacchierotti C et al. "Melatonin in psychiatric disorders: a reviewon the melatonin involvement in psychiatry." Front Neuroendocrinol.22, 1:18-32, 2001. www.sciencedirect.com/science/journal/00913022

27. Varma A et al. "The effect of antidepressants on serum melatoninvalues in endogenous depression." J Assoc Physicians India.50:1262-5, 2002.

28. Karadottir R, Axelsson J. "Melatonin secretion in SAD patients andhealthy patients matched with respect to age and sex." Int J CircumpolarHealth. 60, 4:548-51, 2001.

29. Leppamaki S et al. "Effect of controlled-release melatonin on sleepquality, mood and quality of life in subjects with seasonal orweather-associated changes in mood and behavior." EurNeuropsychopharmacol. 13, 3:137-45, 2003. www.sciencedirect.com/science/journal/0924977X

30. Raghavendra V, Kaur G, Kulkarni SK. "Anti-depressant action ofmelatonin in chronic forced swimming-induced behavioral despair in mice, role ofperipheral benzodiazepine receptor modulation." Eur Neuropsychopharmacol.10, 6:473-81, 2000. www.sciencedirect.com/science/journal/0924977X

31. Nava F, Carta G. "Melatonin reduces anxiety induced bylipopolysaccharide in the rat." Neurosci Lett. 307, 1:57-60, 2001. www.elsevier.nl/locate/neulet

32. Binello E, Gordon CM. "Clinical uses and misuses ofdehydroepiandrosterone." Curr Opin Pharmacol. 3, 6:635-41, 2003. www.co-pharmacol.com

33. Cogan E. "[DHEA: orthodox or alternative medicine?]" Rev MedBrux. 22, 4:A381-6, 2001.

34. van Broekhoven F, Verkes RJ. "Neurosteroids in depression: areview." Psychopharmacology (Berl). 165, 2:97-110, 2003.

35. Young AH, Gallagher P, Porter RJ. "Elevation of thecortisol-dehydroepiandrosterone ratio in drug-free depressed patients." AmJ Psychiatry. 159, 7:1237-9, 2002. http://ajp.psychiatryonline.org

36. Goodyer IM, Herbert J, Tamplin A. "Psychoendocrine antecedents ofpersistent first-episode major depression in adolescents: a community-basedlongitudinal inquiry." Psychol Med. 33, 4:601-10, 2003.

37. McGrath-Hanna K et al. "Diet and mental health in the Arctic: isdiet an important risk factor for mental health in circumpolar people?--areview." Int J Circumpolar Health. 62, 3:228-41, 2003.

38. Tanskanen A et al. "Fish consumption and depressive symptoms in thegeneral population in Finland." Psychiatr Serv. 52, 4:529-31, 2001. http://psychservices.psychiatryonline.org

39. Hakkarainen R et al. "Is low intake of omega-3 fatty acidsassociated with depression?" Am J Psychiatry. 161, 3:567-9, 2004. http://ajp.psychiatryonline.org

40. Tiemeier H et al. "Plasma fatty acid composition and depression areassociated in the elderly: the Rotterdam Study." Am J Clin Nutr. 78,1:40-6, 2003. www.ajcn.org

41. Mamalakis G et al. "Depression and adipose polyunsaturated fattyacids in the survivors of the Seven Countries Study population of Crete." ProstaglandinsLeukot Essent Fatty Acids. 70, 6:495-501, 2004. www.harcourt-international.com/journals/plef

42. Severus WE, Littman AB, Stoll AL. "Omega-3 fatty acids, homocysteineand the increased risk of cardiovascular mortality in major depressivedisorder." Harv Rev Psychiatry. 9, 6:280-93, 2001.

43. Assies J et al. "Fatty acids and homocysteine levels in patientswith recurrent depression: an explorative pilot study." ProstaglandinsLeukot Essent Fatty Acids. 70, 4:349-56, 2004. www.harcourt-international.com/journals/plef

44. Frasure-Smith N, Lesperance F, Julien P. "Major depression isassociated with lower omega-3 fatty acid levels in patients with recent acutecoronary syndromes." Biol Psychiatry. 55, 9:891-6, 2004. www.sciencedirect.com/science/journal/00063223

45. Peet M, Horrobin DF. "A dose-ranging study of the effects ofethyl-eicosapentaenoate in patients with ongoing depression despite apparentlyadequate treatment with standard drugs." Arch Gen Psychiatry. 59,10:913-9, 2002. http://archpsyc.ama-assn.org

46. Fux M, Benjamin J, Nemets B. "A placebo-controlled crossover trialof adjunctive EPA in OCD." J Psychiatr Res. 38, 3:323-5, 2004. www.sciencedirect.com/science/journal/00223956

47. Zanarini MC, Frankenburg FR. "omega-3 Fatty acid treatment of womenwith borderline personality disorder: a double blind, placebo-controlled pilotstudy." Am J Psychiatry. 160, 1:167-9, 2003. http://ajp.psychiatryonline.org

48. Beaubrun G, Gray GE. "A review of herbal medicines for psychiatricdisorders." Psychiatr Serv. 51, 9:1130-4, 2000. http://psychservices.psychiatryonline.org

49. Schulte-Lobbert S et al. "Comparison of the synaptosomal uptakeinhibition of serotonin by St. John's wort products." J Pharm Pharmacol.56, 6:813-8, 2004. http://jpp.pharmpress.com/content/html/index.htm

50. Rodriguez-Landa JF, Contreras CM. "A review of clinical andexperimental observations about antidepressant actions and side effects producedby Hypericum perforatum extracts." Phytomedicine. 10, 8:688-99,2003. www.urbanfischer.de/journals/frame_template.htm?/journals/phytomed/phytmed.htm

51. Kasper S, Dienel A. "Cluster analysis of symptoms duringantidepressant treatment with Hypericum extract in mildly to moderatelydepressed out-patients. A meta-analysis of data from three randomized,placebo-controlled trials." Psychopharmacology (Berl). 164, 3:301-8,2002.

52. Roder C, Schaefer M, Leucht S. "[Meta-analysis of effectiveness andtolerability of treatment of mild to moderate depression with St. John'swort.]" Fortschr Neurol Psychiatr. 72, 6:330-43, 2004.

53. Hypericum Depression Trial Study Group. "Effect of Hypericumperforatum (St. John's wort) in major depressive disorder: a randomizedcontrolled trial." JAMA. 287, 14:1807-14, 2002. www.jama.com

54. Werneke U, Horn O, Taylor DM. "How effective is St. John's wort? Theevidence revisited." J Clin Psychiatry. 65, 5:611-7, 2004. www.psychiatrist.com

55. Kirsch I. "St. John's wort, conventional medication and placebo: anegregious double standard." Complement Ther Med. 11, 3:193-5, 2003. www.sciencedirect.com/science/journal/09652299

56. Izzo AA. "Drug interactions with St. John's wort (Hypericumperforatum): a review of the clinical evidence." Int J Clin PharmacolTher. 42, 3:139-48, 2004.

57. Pittler MH, Ernst E. "Kava extract for treating anxiety." CochraneDatabase Syst Rev. 1:CD003383, 2003. www.cochrane.org

58. Geier FP, Konstantinowicz T. "Kava treatment in patients withanxiety." Phytother Res. 18, 4:297-300, 2004. www.interscience.wiley.com/jpages/0951-418X

59. Lehrl S. "Clinical efficacy of kava extract WS 1490 in sleepdisturbances associated with anxiety disorders. Results of a multicenter,randomized, placebo-controlled, double blind clinical trial." J AffectDisord. 78, 2:101-10, 2004. www.elsevier.nl/locate/jad

60. Gastpar M, Klimm HD. "Treatment of anxiety, tension and restlessnessstates with Kava special extract WS 1490 in general practice: a randomizedplacebo-controlled, double blind multicenter trial." Phytomedicine.10, 8:631-9, 2003. www.urbanfischer.de/journals/frame_template.htm?/journals/phytomed/phytmed.htm

61. Singh YN, Singh NN. "Therapeutic potential of kava in the treatmentof anxiety disorders." CNS Drugs. 16, 11:731-43, 2002.

62. Stickel F et al. "Hepatitis induced by Kava (Piper methysticumrhizoma)." J Hepatol. 39, 1:62-7, 2003. www.jhep-elsevier.com

63. Hadley S, Petry JJ. "Valerian." Am Fam Physician. 67,8:1755-8, 2003. www.aafp.org/afp

64. Andreatini R et al. "Effect of valepotriates (valerian extract) ingeneralized anxiety disorder: a randomized placebo-controlled pilot study."Phytother Res. 16, 7:650-4, 2002. www.interscience.wiley.com/jpages/0951-418X

65. Yuan CS et al. "The gamma-aminobutyric acidergic effects of valerianand valerenic acid on rat brainstem neuronal activity." Anesth Analg.98, 2:353-8, 2004. www.anesthesia-analgesia.org

66. Huen MS et al. "5,7-Dihydroxy-6-methoxyflavone, a benzodiazepinesite ligand isolated from Scutellaria baicalensis Georgi, with selectiveantagonistic properties." Biochem Pharmacol. 66, 1:125-32, 2003. www.elsevier.com/locate/biochempharm

67. Hui KM et al. "Anxiolytic effect of wogonin, a benzodiazepinereceptor ligand isolated from Scutellaria baicalensis Georgi." BiochemPharmacol. 64, 9:1415-24, 2002. www.elsevier.com/locate/biochempharm